Somatostatin receptor imaging and therapy of pancreatic endocrine tumors.
Somatostatin receptors (SS-Rs) have been found on a variety of neuroendocrine tumors like carcinoids, paragangliomas, as well as on brain and breast tumors. SS-Rs are also present on most pancreatic endocrine tumors, while previous in vitro studies indicate the absence of these receptors on pancreatic duct cancers. Somatostatin receptor scintigraphy with a radionuclide labeled somatostatin analogue, [111In-DTPA0]-octreotide, is a sensitive and specific technique to visualize in vivo the presence of SS-Rs on various tumors. The purpose of this article is to review the somatostatin receptor imaging of pancreatic endocrine tumors and to illustrate the impact of SS-R expression for therapeutic strategies.
van Eijck
C H
CH
Department of Surgery, Erasmus Medical Center Rotterdam, The Netherlands. vaneijck@hlkd.azr.nl
de Jong
M
M
Breeman
W A
WA
Slooter
G D
GD
Marquet
R L
RL
Krenning
E P
EP
D001079:Apudoma / Q000737:chemistry / Q000532:radiotherapy*; D006801:Humans; D007205:Indium Radioisotopes / Q000627:therapeutic use; D015282:Octreotide / Q000378:metabolism / Q000627:therapeutic use; D010190:Pancreatic Neoplasms / Q000737:chemistry / Q000532:radiotherapy*; D004369:Pentetic Acid; D017481:Receptors, Somatostatin / Q000032:analysis*
D007205:Indium Radioisotopes; D017481:Receptors, Somatostatin; D004369:Pentetic Acid; D015282:Octreotide